Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011, Article ID 517561, 8 pages
http://dx.doi.org/10.1155/2011/517561
Research Article

Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients

1Department of Medicine, University of Florida, Gainesville, FL 32610, USA
2Departments of Epidemiology and Health Policy Research, University of Florida, Gainesville, FL 32611, USA

Received 6 June 2011; Revised 26 September 2011; Accepted 11 October 2011

Academic Editor: J. F. San Miguel

Copyright © 2011 Jan S. Moreb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. C. Pasquini, Z. Wang, and L. Schneider, “CIBMTR summary slides part 1,” CIBMTR Newsletter, vol. 135, article 8, 2007. View at Google Scholar
  2. N. Schmitz, D. C. Linch, P. Dreger et al., “Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients,” Lancet, vol. 347, no. 8998, pp. 353–357, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Kanteti, K. B. Miller, J. C. McCann et al., “Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis,” Bone Marrow Transplantation, vol. 24, no. 5, pp. 473–481, 1999. View at Google Scholar · View at Scopus
  4. T. J. Smith, B. E. Hillner, N. Schmitz et al., “Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 5–10, 1997. View at Google Scholar · View at Scopus
  5. M. Lopez, F. M. Lemoine, H. Firat et al., “Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting,” Blood, vol. 90, no. 7, pp. 2830–2838, 1997. View at Google Scholar · View at Scopus
  6. S. Boeve, J. Strupeck, S. Creech, and P. J. Stiff, “Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost,” Bone Marrow Transplantation, vol. 33, no. 10, pp. 997–1003, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. I. Pusic, S. Y. Jiang, S. Landua et al., “Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation,” Biology of Blood and Marrow Transplantation, vol. 14, no. 9, pp. 1045–1056, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. M. Vose, A. D. Ho, B. Coiffier et al., “Advances in mobilization for the optimization of autologous stem cell transplantation,” Leukemia and Lymphoma, vol. 50, no. 9, pp. 1412–1421, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. R. Goterris, J. C. Hernández-Boluda, A. Teruel et al., “Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers,” Bone Marrow Transplantation, vol. 36, no. 10, pp. 847–853, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. W. Sugrue, K. Williams, B. H. Pollock et al., “Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation,” Leukemia and Lymphoma, vol. 39, no. 5-6, pp. 509–519, 2000. View at Google Scholar · View at Scopus
  11. L. N. Gordan, M. W. Sugrue, J. W. Lynch et al., “Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation,” Leukemia and Lymphoma, vol. 44, no. 5, pp. 815–820, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Tomblyn, L. J. Burns, B. Blazar et al., “Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma,” Bone Marrow Transplantation, vol. 40, no. 2, pp. 111–118, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. V. Pavone, F. Gaudio, G. Console et al., “Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation,” Bone Marrow Transplantation, vol. 37, no. 8, pp. 719–724, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. G. Tricot, M. H. Cottler-Fox, and G. Calandra, “Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization,” Bone Marrow Transplantation, vol. 45, no. 1, pp. 63–68, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. F. DiPersio, E. A. Stadtmauer, A. Nademanee et al., “Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma,” Blood, vol. 113, no. 23, pp. 5720–5726, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. F. DiPersio, I. N. Micallef, P. J. Stiff et al., “Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4767–4773, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. G. Calandra, J. McCarty, J. McGuirk et al., “AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data,” Bone Marrow Transplantation, vol. 41, no. 4, pp. 331–338, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. C. R. Cogle, J. S. Moreb, H. L. Leather et al., “Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma,” American Journal of Hematology, vol. 73, no. 3, pp. 169–175, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. R. F. Duarte, B. E. Shaw, P. Marín et al., “Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data,” Bone Marrow Transplantation, vol. 46, pp. 52–58, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. J. Fowler, A. Dunn, B. Hayes-Lattin et al., “Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience,” Bone Marrow Transplantation, vol. 43, no. 12, pp. 909–917, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. S. Moreb, “Plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients undergoing autologous stem cell transplantation,” Oncology Reviews, vol. 5, no. 1, pp. 67–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. I. N. Micallef, P. J. Stiff, J. F. DiPersio et al., “Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol,” Biology of Blood and Marrow Transplantation, vol. 15, no. 12, pp. 1578–1586, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. H. Y. Choi, C. S. Yong, and B. K. Yoo, “Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma,” Annals of Pharmacotherapy, vol. 44, no. 1, pp. 117–126, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. Cashen, S. Lopez, F. Gao et al., “A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma,” Biology of Blood and Marrow Transplantation, vol. 14, no. 11, pp. 1253–1261, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. J. Dugan, R. T. Maziarz, W. I. Bensinger et al., “Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization,” Bone Marrow Transplantation, vol. 45, no. 1, pp. 39–47, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. A. D, A. Curti, N. Worel et al., “The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF,” Bone Marrow Transplantation, vol. 46, no. 3, pp. 356–363, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. Stiff, I. Micallef, P. McCarthy et al., “Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient,” Biology of Blood and Marrow Transplantation, vol. 15, no. 2, pp. 249–256, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. S. Fruehauf, M. R. Veldwijk, T. Seeger et al., “A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study,” Cytotherapy, vol. 11, no. 8, pp. 992–1001, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. V. Fraipont, B. Sautois, E. Baudoux et al., “Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF,” Transfusion, vol. 40, no. 3, pp. 339–347, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Perseghin, E. Terruzzi, M. Dassi et al., “Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions,” Transfusion and Apheresis Science, vol. 41, no. 1, pp. 33–37, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. S. Kumar, A. Dispenzieri, M. Q. Lacy et al., “Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma,” Leukemia, vol. 21, no. 9, pp. 2035–2042, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. U. Popat, R. Saliba, R. Thandi et al., “Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma,” Biology of Blood and Marrow Transplantation, vol. 15, no. 6, pp. 718–723, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. I. N. M. Micallef, A. D. Ho, L. M. Klein, S. Marulkar, P. J. Gandhi, and P. A. McSweeney, “Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide,” Bone Marrow Transplantation, vol. 46, no. 3, pp. 350–355, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus